Dulaglutide Legal Status: Approval, Research Use, and Regulatory Notes
FDA approved (2014). Prescription required. Not a controlled substance.
Direct Answer
Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Type 2 diabetes management, cardiovascular risk reduction, once-weekly GLP-1 agonism
Legal and Regulatory Status
FDA approved (2014). Prescription required. Not a controlled substance.
Approval Stage
Dulaglutide is listed as FDA Approved. Approved uses, if any, are indication-specific and do not automatically apply to other claims.
Compliance Notes
- Boxed warning: Thyroid C-cell tumor risk in rodents
- Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2
- Risk of pancreatitis - discontinue if suspected
- Caution in patients with renal impairment
- Not for use in type 1 diabetes or diabetic ketoacidosis
Evidence Page
For the complete evidence review, see the main Dulaglutide guide linked below.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Glycemic Control (Level A), Cardiovascular Risk Reduction (Level A), and Body Weight Reduction (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Dulaglutide Legal Status: Approval, Research Use, and Regulatory Notes." Last reviewed 2026-04-04. https://examinepeptides.com/answers/dulaglutide-legal-status/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.